Compare Citigroup Inc. (C) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citigroup Inc. vs Zoetis Inc — how do they compare? Citigroup Inc. trades at $137.59 (market cap $227.75B), while Zoetis Inc trades at $72.48 (market cap $31.14B). The key difference: Citigroup Inc. is far larger — about 7.3× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.81%). Which is the better fit depends on your goals.
| C | ZTS | |
|---|---|---|
Market Cap | $227.75B | $31.14B |
Sector | Financials | Health |
52-Week High | $145.67 | $156.76 |
52-Week Low | $92.59 | $71.91 |
Dividend Yield | 1.97% | 2.81% |
Enterprise Value | — | $38.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Citigroup (C) trades at $137.78, up 1.89% today, with a bullish technical signal from moving averages and a consensus analyst price target of $154.38. Recent Q2 2026 earnings beat expectations with EPS of $3.15 versus $2.72 expected, while revenue reached a decade high. The company is actively hiring senior bankers and launching digital trade solutions, signaling strategic growth initiatives.
The outlook is positive, supported by earnings momentum and a 59% analyst buy rating, but risks include volatile cash flows from operations and high leverage. The stock offers potential upside to the price target, with investor focus on execution of the medium-term ROTCE target of 14-15%.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citigroup Inc.
Citigroup Inc. is a diversified financial services holding company that provides a broad range of financial services to consumer and corporate customers. The Company services include investment banking, retail brokerage, corporate banking, and cash management products and services. Citigroup serves customers globally.
Read more on C →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
